# ULTRAS (NCT06362395)

> Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: liver metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06362395
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University Health Network, Toronto
- Conditions: Liver Metastases
- Interventions: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
- Enrollment: 114
- Primary outcome: Local control (LC) of treated target lesion compared to high dose MR-guided stereotactic single-fraction radiation.

## Indexed commentary on ULTRAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ultras-nct06362395

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06362395", "email": "<work email>"}; the inbox owner confirms by the emailed link.